FGF2-based dual warhead conjugate not only kills cancer cells more efficiently than single drug conjugates, but also has the potential to limit the ability of cancer cells to develop resistance to cytotoxic drugs, which is a well-known feature of various cancers [17,18]. The gene discussed is FGF2; the disease is cancer.